Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Proxima AI Technology Co., Ltd has reportedly raised over RMB 100 million (USD 14.8 million) in a strategic financing round. The round was led by Fosun Pharma and Guoyao Zhongjin (Shanghai) Medical Health Investment Management, with Anting Industrial also participating.
Market Outlook
The medical artificial intelligence (AI) market in China is projected to exceed RMB 100 billion (USD 14.8 billion) by 2030. Proxima AI, founded in 2018, specializes in the R&D, manufacturing, and sales of medical imaging and pathology AI software and digital solutions.
Product Pipeline
Proxima AI’s offerings include imaging, pathology, and information systems. Its PYXIS digital microscopic image analysis system features an automatic micro scanner and AI analysis module, enabling a one-stop pathology service process. The system’s digital microscopic scanning can operate unattended, with a single device capable of over a thousand scans daily, significantly improving doctor efficiency (2 to 3 times faster than traditional manual reading).-Fineline Info & Tech
